CDMO News and Research

RSS

Celltrion and Emory University sign 'Incubation' agreement to develop new drug candidates for atherosclerosis

Celltrion, Inc. signed an 'Incubation' agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.

20 Sep 2018

Ology Bioservices wins $8.4 million worth agreement to manufacture anti-Ebola monoclonal antibody

Ology Bioservices, Inc., a biologics contract development and manufacturing organization, announced today that it was awarded an Other Transaction Agreement to support the Joint Project Manager Medical Countermeasure Systems, a component of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense for advanced biologics manufacturing services—specifically, to manufacture an anti-Ebola monoclonal antibody.

17 Aug 2018

Minakem's new high-class production facility extends capacity to develop and manufacture HPAPI compounds

Minakem, the CDMO division of Minafin, specialized in custom development and manufacturing of building blocks, GMP intermediates and Active Pharmaceutical Ingredients, today announces it is in the final qualification run to open a new closed-controlled environment high containment production facility in August.

22 Jun 2018

Vetter's new campaign aims to examine applicability of digital trends to injection systems

How can digital trends be used purposefully in regards to the application of injection systems? That is the key question being addressed by Vetter’s Open Innovation Challenge.

13 Jun 2018

Abzena selects Sartorius Stedim Biotech as preferred equipment supplier in the U.S

Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.

From Sartorius 9 Feb 2018

CPhI Pre-Connect Congress to provide insights on major developments in pharmaceutical industry

CPhI Worldwide, organized by UBM EMEA, announces the upcoming trends in the 8th edition of the CPhI Pre-Connect Congress, taking place on October 3rd.

26 Aug 2016

Xcelience announces grand opening of new headquarters in Tampa

Xcelience is proud to announce the grand opening of its new 71,000 square foot headquarters located at 4910 Savarese Circle in Tampa. The building houses preformulation and formulation development labs and suites, as well as analytical and stability services. The official ribbon cutting ceremony was attended by Florida Governor Rick Scott, Tampa Mayor Bob Buckhorn and other elected and non-elected officials.

31 Oct 2015

Lupin signs strategic asset purchase agreement with Temmler

Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.

25 Jul 2015

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Takara Bio Europe AB, formerly Cellartis AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching an advanced cell culture medium for iPS cell culture. This chemically-defined culture medium is pre-clinical grade, free from human- and animal-derived components, and designed for efficient expansion of undifferentiated human iPS cells.

3 Jun 2015

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

11 May 2015

CDMO News and Research

Celltrion and Emory University sign 'Incubation' agreement to develop new drug candidates for atherosclerosis

Ology Bioservices wins $8.4 million worth agreement to manufacture anti-Ebola monoclonal antibody

Minakem's new high-class production facility extends capacity to develop and manufacture HPAPI compounds

Vetter's new campaign aims to examine applicability of digital trends to injection systems

Abzena selects Sartorius Stedim Biotech as preferred equipment supplier in the U.S

CPhI Pre-Connect Congress to provide insights on major developments in pharmaceutical industry

Xcelience announces grand opening of new headquarters in Tampa

Lupin signs strategic asset purchase agreement with Temmler

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Particle Sciences receives patent for its surface arrayed therapeutics drug delivery platform

Particle Sciences to expand sterile manufacturing for complex products and particulates

Particle sciences manufactures clinical supplies for Kinex’s glioblastom therapeutic

Marken launches new marketing campaign to solidify its place as industry's only Clinical Logistics Organization

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News